ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
51 announcements with these filters
Q2 consolidated revenue ₹105.61 Cr (+102%), PAT ₹17.18 Cr (+84%). EBITDA margin recovered to 23.9%, still below the 25-30% guided band. FY27 revenue reiterated at ₹380-400 Cr.
Q2FY27 consolidated revenue ₹105.6 Cr (+102.3% YoY), EBITDA ₹25.2 Cr (+84.1%), PAT ₹17.2 Cr (+84.4%). H1 FY27 revenue ₹193.2 Cr (+125.9%). Strategy: integrated API-to-formulations platform.
Anlon Healthcare Ltd reported revenue from operations of ₹105.6 Cr (+102.3% YoY) and net profit of ₹17.2 Cr (+84.9% YoY) for Q2 FY27.
Anlon Healthcare received NSE and BSE in-principle approval for 8,05,35,651 preferential shares under a share swap. No cash consideration is stated.
Anlon Healthcare will hold a board meeting on 29 October 2026 to consider unaudited standalone and consolidated half-yearly results. The trading window is closed from 1 October to 31 October 2026.
Anlon Healthcare Limited filed the mandatory Regulation 74(5) certificate from its Registrar and Share Transfer Agent for the quarter ended September 30, 2026.
Anlon Healthcare approved a preferential issue of convertible warrants for up to Rs. 250 Crore to raise funds for the company.
Anlon Healthcare Ltd scheduled a board meeting for October 13, 2026, to deliberate on business expansion plans and potential fund-raising.
Anlon Healthcare incorporated ANLON Healthcare Nigeria Limited, holding 90% stake. The subsidiary aims to expand pharmaceutical and healthcare operations across 16 West African countries.
Anlon Healthcare's AGM approved acquiring Apiqo Organics and Bizotic Lifescience stakes via share swap. The filing adds preferential issue pricing of ₹17.85 per share.
Anlon Healthcare responded to NSE/BSE surveillance queries stating no undisclosed information explains the price movement. The company attributes the move to market-driven factors.
Brickwork Ratings assigned BWR BBB/Stable to Anlon Healthcare's ₹23.60 Crore fund-based term loan. The rating reflects improved profitability and low leverage following the company's 2025 IPO.
Anlon Healthcare Limited held its 13th Annual General Meeting on September 05, 2025. Shareholders considered financial statements, director appointments, and a preferential issue of equity shares.
Anlon Healthcare issued a corrigendum to its 13th AGM Notice, revising details for proposed preferential share allotments. The AGM is scheduled for September 5, 2026.
Anlon Healthcare Limited issued a notice for its 13th Annual General Meeting on September 5, 2026. The agenda includes financial statements and director appointments.
Anlon Healthcare Limited has filed its Annual Report for the financial year 2025-2026. This submission complies with Regulation 34 of the SEBI Listing Regulations.
Anlon Healthcare's 13th AGM, scheduled for September 5, 2026, proposes key business items, including the acquisition of Apiqo Organics and share capital enhancement.
Anlon Healthcare Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026, as required under SEBI regulations.
Anlon Healthcare will acquire significant stakes in Apiqo Organics (44.94%) and Bizotic Lifescience (47.41%) for a total consideration of approximately ₹153.30 Crore. Acquisitions involve a share swap via preferential issue.
Anlon Healthcare Q1 FY27 results show strong top-line growth following the acquisition of Remember India Health Links, though EBITDA margins faced temporary pressure from surging raw material costs and consolidation expenses.
Anlon Healthcare executed agreements to acquire stakes in Apiqo Organics and Bizotic Lifescience via share swaps. The AOPL acquisition is valued at approximately ₹116.52 Crore.
Anlon Healthcare will hold a board meeting on August 11, 2026, to consider financial results, share capital changes, and preferential equity issuances for acquisitions.
Anlon Healthcare is transitioning to an integrated pharma player via strategic acquisitions. Reported FY26 revenue of ₹171.97 Cr with a 27.74% EBITDA margin, focusing on backward integration and high-value APIs.
Anlon Healthcare Limited reported Q1FY27 consolidated net profit growth of 133% to ₹8.28 Crore. Total income rose 163% to ₹87.62 Crore, driven by strategic acquisitions.
Anlon Healthcare Ltd reported revenue from operations of ₹87.6 Cr (+163.1% YoY) and net profit of ₹8.3 Cr (+137.1% YoY) for Q1 FY27.
Anlon Healthcare Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026. The filing discloses the company's current equity ownership distribution.
Anlon Healthcare scheduled a board meeting for July 30, 2026, to approve quarterly financial results and authorize the acquisition of shares in AOPL and BLPL.
Anlon Healthcare Ltd submitted its shareholding pattern for the quarter ended June 30, 2026, as per regulatory requirements.
Anlon Healthcare incorporated a 65% subsidiary, Anlon Biologics Private Limited, for Rs. 0.065 Crore. The unit will manufacture surgical implants and biosimilars.
Anlon Healthcare incorporated a 55% subsidiary, Anlon Medicare Private Limited, for Rs. 0.11 Crore. The new unit will manufacture surgical implants and medical devices.